Patents by Inventor Sean C. Semple
Sean C. Semple has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10653780Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: August 28, 2015Date of Patent: May 19, 2020Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Publication number: 20160095924Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: August 28, 2015Publication date: April 7, 2016Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Patent number: 9139554Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: October 9, 2009Date of Patent: September 22, 2015Assignees: Tekmira Pharmaceuticals Corporation, The University of British ColumbiaInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Publication number: 20130136787Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: ApplicationFiled: June 28, 2012Publication date: May 30, 2013Applicant: Talon Therapeutics, Inc.Inventors: Thomas D. Madden, Sean C. Semple
-
Publication number: 20120114831Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: ApplicationFiled: August 1, 2011Publication date: May 10, 2012Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Publication number: 20110256175Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: October 9, 2009Publication date: October 20, 2011Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Patent number: 8021686Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: GrantFiled: February 8, 2008Date of Patent: September 20, 2011Assignee: The University of British ColumbiaInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter R. Cullis, Peter Scherrer, Dan Debeyer
-
Publication number: 20110117125Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: December 31, 2008Publication date: May 19, 2011Applicants: TEKMIRA PHARMACEUTICALS CORPORATION, THE UNIVERSITY OF BRITISH COLUMBIA, ALNYLAM PHARMACEUTICALSInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Barbara Mui, Pieter R. Cullis, Marco A. Ciufolini, Kim F. Wong, Muthiah Manoharan, Rajeev G. Kallanthottathil
-
Patent number: 7811602Abstract: The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.Type: GrantFiled: May 16, 2005Date of Patent: October 12, 2010Assignee: Tekmira Pharmaceuticals CorporationInventors: Pieter R Cullis, Thomas D Madden, Michael J Hope, Steven M Ansell, Barbara L S Mui, Sean C Semple, Norbert Maurer
-
Patent number: 7452550Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: GrantFiled: May 9, 2006Date of Patent: November 18, 2008Assignee: Hana Biosciences, Inc.Inventors: Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
-
Publication number: 20080200417Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: ApplicationFiled: February 8, 2008Publication date: August 21, 2008Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 7341738Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: GrantFiled: September 9, 2003Date of Patent: March 11, 2008Assignee: The University of British ColumbiaInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 7311924Abstract: This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.Type: GrantFiled: April 3, 2003Date of Patent: December 25, 2007Assignee: Hana Biosciences, Inc.Inventors: Andreas H Sarris, Fernando Cabanillas, Patricia M Logan, Clive T R Burge, James H Goldie, Murray S Webb, Thomas D Madden, Sean C Semple, Quet F Ahkong, Sandra K Klimuk
-
Patent number: 7244448Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: GrantFiled: June 29, 2001Date of Patent: July 17, 2007Assignee: Tekmira Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
-
Patent number: 7060828Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: GrantFiled: June 29, 2001Date of Patent: June 13, 2006Assignee: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple
-
Patent number: 6858225Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: GrantFiled: June 29, 2001Date of Patent: February 22, 2005Assignee: Inex Pharmaceuticals CorporationInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 6835395Abstract: Lipidic compositions with superior characteristics for in vivo delivery of oligodeoxynucleotides (ODN) can easily and efficiently be made in the form of small multilamellar vesicles. The compositions contain a population of nucleic acid-containing lipid vesicles in a liquid carrier, and at least a portion of the lipid vesicles are small multilamellar vesicles. The small multilamellar vesicles are made from a lipid component including 20-30 mol % of an ionizable amino lipid such as DODAP, and a steric barrier lipid such as PEG-CerC14; and an oligodeoxynucleotide contained in the lumen or interlamellar spaces of the small multilamellar vesicles. The ODN and lipid components are preferably present in the small multilamellar vesicles in a mole ratio of from 0.15 to 0.25.Type: GrantFiled: September 1, 2000Date of Patent: December 28, 2004Assignee: The University of British ColumbiaInventors: Sean C. Semple, Sandra K. Klimuk, Troy O. Harasym, Nancy Dos Santos, Steven M. Ansell, Pieter R Cullis, Michael J. Hope, Peter Scherrer, Deirdre McIntosh, Kim F. Wong, Norbert Maurer
-
Publication number: 20040170678Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: ApplicationFiled: February 27, 2004Publication date: September 2, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
-
Publication number: 20040071768Abstract: This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.Type: ApplicationFiled: April 3, 2003Publication date: April 15, 2004Applicants: Inex Pharmaceuticals Corporation, The University of Texas, MD Anderson Cancer CenterInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb, Thomas D. Madden, Sean C. Semple, Quet F. Ahkong, Sandra K. Klimuk
-
Publication number: 20040013649Abstract: The invention discloses cancer vaccines comprising lipid-nucleic acid formulations in combination with one or more tumor-associated antigens which are capable of stimulating strong, Th-1 biased cellular immune responses to said tumor-associated antigens in vivo. It is further disclosed the subject cancer vaccines provide therapeutic efficacy in treating tumors in an animal.Type: ApplicationFiled: May 12, 2003Publication date: January 22, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Ying Kee Tam, Sean C. Semple, Sandra K. Klimuk, Ghania Chikh